|
1
|
Li Y, Fang Z, Ge S, Li J, Qu L, Shi X, Zhang W, Sun Y, Ren S, Wang L. Long non-coding RNA ENST00000503625 is a potential prognostic biomarker and metastasis suppressor gene in prostate cancer. J Cancer Res Clin Oncol 2023; 149:7305-7317. [PMID: 36920562 DOI: 10.1007/s00432-023-04676-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2022] [Accepted: 03/04/2023] [Indexed: 03/16/2023]
Abstract
BACKGROUND Dysregulation of Long Non-coding RNAs (lncRNAs) emerges to be a hallmark of cancers. Metastatic prostate cancer and localized disease that recurs after treatment are clinical challenges, it remains unclear how lncRNA plays a role in those processes. METHODS From previous RNA-Seq data on 65 prostate cancer and adjacent normal tissues. We identified a novel lncRNA ENST00000503625 down-regulated in prostate cancer and correlated with tumor progression characteristics. Public datasets were examined for associations between ENST00000503625 expression and clinical parameters and prognoses. Subsequently, we constructed and externally validated a nomogram for predicting biochemical recurrence (BCR). Finally, in vitro experiments were carried out to determine how ENST00000503625 functions biologically in prostate cancer. RESULTS Low ENST00000503625 in tumor was associated with poor clinical features and prognoses. TCGA pan-cancer analysis found that ENST00000503625 was deregulated in a variety of tumors and correlated with overall survival, disease-specific survival, and progression-free survival. The nomogram for predicting BCR was constructed using TCGA data, which exhibited excellent accuracy in external validation with Chinese Prostate Cancer Genome and Epigenome Atlas data. Gene Ontology and KEGG pathway analysis found that genes related to ENST00000503625 were enriched in multiple tumor progression related pathways. When ENST00000503625 was knocked down in vitro, the epithelial-mesenchymal transition was induced, by which cancer cells migrated and invaded more readily. CONCLUSION Our data suggested that ENST00000503625 may serve as a potential prognostic marker or a therapeutic target for prostate cancer metastases.
Collapse
Affiliation(s)
- Yaoming Li
- Department of Urology, Institute of Surgery Research, Daping Hospital/Army Medical Center, Army Medical University, Chongqing, 400042, China
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China
| | - Ziyu Fang
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China
| | - Silun Ge
- Department of Urology, Jinling Hospital, Nanjing Medical University, Nanjing, 201101, China
| | - Jingyi Li
- Department of Urology, Institute of Surgery Research, Daping Hospital/Army Medical Center, Army Medical University, Chongqing, 400042, China
| | - Le Qu
- Department of Urology, Jinling Hospital, Nanjing Medical University, Nanjing, 201101, China
| | - Xiaolei Shi
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China
| | - Wei Zhang
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China
| | - Yinghao Sun
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China
| | - Shancheng Ren
- Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
| | - Luofu Wang
- Department of Urology, Institute of Surgery Research, Daping Hospital/Army Medical Center, Army Medical University, Chongqing, 400042, China.
| |
Collapse
|